{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:56:28Z","timestamp":1790628988682,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.ygyno.2009.11.009","type":"journal-article","created":{"date-parts":[[2009,12,3]],"date-time":"2009-12-03T09:59:56Z","timestamp":1259834396000},"page":"345-350","source":"Crossref","is-referenced-by-count":27,"title":["Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications"],"prefix":"10.1016","volume":"116","author":[{"given":"Jamie L.","family":"Lesnock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin K.","family":"Zorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Krivak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil","family":"Beriwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paniti","family":"Sukumvanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"William C.","family":"McBee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2009.11.009_bib1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2009.11.009_bib2","unstructured":"http:\/\/www.cancer.gov"},{"issue":"26","key":"10.1016\/j.ygyno.2009.11.009_bib3","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"35","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ygyno.2009.11.009_bib4","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2009.11.009_bib5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2009.11.009_bib6","unstructured":"www.nlm.nih.gov\/databases\/alerts\/ovarian_ip_chemo.html"},{"issue":"1","key":"10.1016\/j.ygyno.2009.11.009_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ygyno.2009.04.001","article-title":"Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer","volume":"114","author":"Naumann","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2009.11.009_bib8","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected Stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.11.009_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.11.009_bib10","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.1992.10.5.706","article-title":"Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer","volume":"10","author":"Alberts","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.11.009_bib11","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1200\/JCO.1992.10.5.718","article-title":"Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials group","volume":"10","author":"Swenerton","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.11.009_bib12","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.1995.13.7.1589","article-title":"Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study","volume":"13","author":"McGuire","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.11.009_bib13","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0959-8049(03)00152-7","article-title":"Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients: 10-year results of a prospective randomized phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin","volume":"39","author":"Dittrich","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2009.11.009_bib14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1006\/gyno.1996.0210","article-title":"Paclitaxel delivered as a 3-hour infusion with cisplatin in patients with gynecologic cancer: unexpected incidence of neurotoxicity","volume":"62","author":"Connelly","year":"1996","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2009.11.009_bib15","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1200\/JCO.2005.05.2456","article-title":"Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment","volume":"24","author":"Markman","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.11.009_bib16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ygyno.2009.05.034","article-title":"Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer","volume":"114","author":"Yen","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.11.009_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.5549","article-title":"The clinical-pathological factors relevant to intraperitoneal chemotherapy in ovarian cancer: an analysis of two Gynecologic Oncology Group trials. 2008 ASCO Annual Meeting","volume":"26","author":"Tewari","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2009.11.009_bib18","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1984.2.11.1277","article-title":"Totally implantable system for peritoneal access","volume":"2","author":"Pfeifle","year":"1984","journal-title":"J. Clin. Oncol."},{"issue":"3 Suppl 4","key":"10.1016\/j.ygyno.2009.11.009_bib19","first-page":"90","article-title":"Intraperitoneal chemotherapy: technical experience at five institutions","volume":"12","author":"Piccart","year":"1985","journal-title":"Semin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2009.11.009_bib20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0090-8258(91)90266-8","article-title":"Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system","volume":"41","author":"Davidson","year":"1991","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2009.11.009_bib21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0090-8258(86)90083-1","article-title":"Technical aspects of intraperitoneal chemotherapy in abdominal carcinomatosis","volume":"25","author":"Braly","year":"1986","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2009.11.009_bib22","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1006\/gyno.2000.5979","article-title":"Complications relating to intraperitoneal administration of cisplatin or carboplatin for ovarian carcinoma","volume":"79","author":"Sakuragi","year":"2000","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2009.11.009_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1006\/gyno.2000.6108","article-title":"Complications associated with intraperitoneal chemotherapy catheters","volume":"81","author":"Makhija","year":"2001","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2009.11.009_bib24","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0090-8258(03)00377-9","article-title":"First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up","volume":"90","author":"Fujiwara","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.11.009_bib25","first-page":"247","article-title":"Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates","volume":"108","author":"Landrum","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.11.009_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ygyno.2007.12.004","article-title":"Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer","volume":"109","author":"Black","year":"2008","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809009500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809009500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T06:00:50Z","timestamp":1558677650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825809009500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0090825809009500"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.11.009","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}